Skip to main content

Table 1 The DOT assignment and multiple replacement sampling results

From: Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs

Sampling number

Patient number from reconstructed IPD

PFS time

PFS censoring

OS time

OS censoring

PD time

Randomized start time of receiving treatment

Date of the end of year

Residual months in the first year

DOT of intervention in the 1st year

DOT of subsequent treatment in the 1st year

DOT of intervention in the 2nd year

DOT of subsequent treatment in the 2nd year

DOT of intervention in the 3rd year

DOT of subsequent treatment in the 3rd year

DOT of intervention in the 4th year

DOT of subsequent treatment in the 4th year

1

114

260.74

1

287.82

1

27.08

01/06

12/31

11.97

11.97

0.00

12.00

0.00

12.00

0.00

12.00

0.00

2

12

1.08

1

2.89

1

1.81

08/26

12/31

4.23

1.08

1.81

0.00

0.00

0.00

0.00

0.00

0.00

3

142

378.10

1

402.66

1

24.56

05/17

12/31

7.60

7.60

0.00

12.00

0.00

12.00

0.00

12.00

0.00

4

117

278.79

1

298.66

1

19.86

02/01

12/31

11.10

11.10

0.00

12.00

0.00

12.00

0.00

12.00

0.00

5

11

1.08

1

2.53

1

1.44

07/24

12/31

5.33

1.08

1.44

0.00

0.00

0.00

0.00

0.00

0.00

6

150

442.39

1

459.36

1

16.97

02/13

12/31

10.70

10.70

0.00

12.00

0.00

12.00

0.00

12.00

0.00

7

109

230.04

1

270.13

1

40.09

01/20

12/31

11.50

11.50

0.00

12.00

0.00

12.00

0.00

12.00

0.00

8

133

353.19

1

362.22

1

9.03

12/22

12/31

0.30

0.30

0.00

12.00

0.00

12.00

0.00

12.00

0.00

9

145

399.41

1

417.11

1

17.70

03/22

12/31

9.47

9.47

0.00

12.00

0.00

12.00

0.00

12.00

0.00

10

144

392.91

1

412.05

1

19.14

05/12

12/31

7.77

7.77

0.00

12.00

0.00

12.00

0.00

12.00

0.00

11

150

442.39

1

459.36

1

16.97

02/13

12/31

10.70

10.70

0.00

12.00

0.00

12.00

0.00

12.00

0.00

12

19

1.81

1

4.69

1

2.89

01/28

12/31

11.23

1.81

2.89

0.00

0.00

0.00

0.00

0.00

0.00

13

82

15.89

1

123.51

1

107.62

03/17

12/31

9.63

9.63

0.00

6.26

5.74

0.00

12.00

0.00

12.00

14

112

248.82

1

282.77

1

33.95

06/27

12/31

6.23

6.23

0.00

12.00

0.00

12.00

0.00

12.00

0.00

15

11

1.08

1

2.53

1

1.44

07/24

12/31

5.33

1.08

1.44

0.00

0.00

0.00

0.00

0.00

0.00

996

19

1.81

1

4.69

1

2.89

01/28

12/31

11.23

1.81

2.89

0.00

0.00

0.00

0.00

0.00

0.00

997

80

14.45

1

112.67

1

98.23

11/29

12/31

1.07

1.07

0.00

12.00

0.00

1.38

10.62

0.00

12.00

998

88

24.92

1

159.62

1

134.70

02/03

12/31

11.03

11.03

0.00

12.00

0.00

1.88

10.12

0.00

12.00

999

41

3.97

1

15.17

1

11.20

12/29

12/31

0.07

0.07

0.00

3.91

8.09

0.00

3.10

0.00

0.00

1000

13

1.44

1

3.25

1

1.81

12/06

12/31

0.83

0.83

0.00

0.61

1.81

0.00

0.00

0.00

0.00

         

Average

4.90

0.75

6.60

2.84

5.24

2.99

5.06

2.5

  1. DOT duration of treatment; IPD individual patient data; OS overall survival; PFS progression-free survival